Nektar Reorganizes To Position Pegylated, Pulmonary Units For Future Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Spending cuts amounting to $65 million annually are not driven by lackluster performance of Exubera, CEO Robin maintains.
You may also be interested in...
Nektar Restructuring Pays Off in Fourth-Quarter Results
New Exubera partner sought by mid-year, two more Phase IIs coming with cancer drug, CEO says.
Nektar Restructuring Pays Off in Fourth-Quarter Results
New Exubera partner sought by mid-year, two more Phase IIs coming with cancer drug, CEO says.
Nektar Cuts Another 150 Jobs In Wake Of Exubera; Sharpens Therapeutic Focus
San Carlos, Calif., firm still shopping for new inhaled-insulin partner.